CompoAtlas

(Genestra Brands) MenoRelief

Testo originale in francese.

Prodotto naturale per la salute autorizzato in Canada

Se questo prodotto fosse venduto in Francia

Nessun punto rilevato secondo le norme che applichiamo.

Si calcola una quantità giornaliera solo per una posologia orale esplicita per adulti, espressa al giorno e in un’unità solida corrispondente alla forma del prodotto. Unità ambigue, liquidi, polveri e dosi pediatriche non vengono estrapolati. Una quantità non calcolata non viene confrontata con i limiti di dose. Questa analisi non costituisce un’autorizzazione alla vendita in Francia né una valutazione di sicurezza o efficacia.

Composizione

Ingrediente medicinale e fontePer unità posologica, secondo la fonteMassimo giornaliero, adulto
Passiflora incarnata

Fonte : Passiflora incarnata - Herb top

Estratto : Matériel brut sec

Rapporto di estrazione : 4-6:1

Equivalente di pianta secca : 200-300 mg

50 mgNon calcolata
Crocus sativus

Fonte : Crocus sativus - Stigmate

Estratto : Matériel brut sec

Rapporto di estrazione : 3:1

Equivalente di pianta secca : 42 mg

Potenza : 3,48 % Crocin

14 mgNon calcolata
Crocus sativus

Fonte : Crocus sativus - Stigmate

Potenza : 0,03 % 2,6,6-Trimethylcyclohexa-1,3-diene-1-carbaldehyde

Non precisataNon calcolata

Ingredienti non medicinali

Cellulose, Hypromellose, Gomme de gellane, Stéarate de magnésium, Maltodextrine

Dosi raccomandate in Canada

PopolazioneEtàQuantità per assunzioneFrequenza
Adultesminimum : 18 ans1 Capsule2 par jour

Usi autorizzati in Canada

Passiflora incarnata is traditionally used in Herbal Medicine as a sleep aid (during times of mental stress). Passiflora incarnata is traditionally used in Herbal Medicine to help relieve restlessness and/or nervousness (nervine/calmative). Used in Herbal Medicine to help relieve restlessness and/or nervousness (calmative). Helps to support mood balance. (affron) Helps to relieve restlessness and/or nervousness (calmative). Supports positive effects on symptoms of perceived stress such as fatigue, weariness, and irritability. Helps to reduce the symptoms of perceived stress, such as fatigue, weariness, and irritability. Helps to improve restorative sleep in individuals experiencing sleeplessness. Helps improve sleep quality in individuals experiencing sleeplessness. Helps to support/maintain (healthy) mood balance. Clinically proven to support/maintain (healthy) mood balance. (affron is) Clinically shown to relieve restlessness and/or nervousness (calmative). Clinically shown to support positive effects on symptoms of perceived stress such as fatigue, weariness, and irritability. Clinically shown to reduce the symptoms of perceived stress such as fatigue, weariness, and irritability. Clinically shown to improve restorative sleep in individuals experiencing sleeplessness. Supports the management of symptoms associated with perimenopause. Helps improves sleep quality. Clinically proven to help improve sleep quality. Clinically proven to help improve sleep quality in 4 weeks. Clinically proven to improve sleep quality in individuals experiencing sleeplessness. May help to support healthy mood balance during perimenopause. Helps to support healthy mood balance during perimenopause. Clinically shown to help relieve symptoms associated with perimenopause. Helps to support mood balance after awakening. Helps to support healthy mood balance after awakening. Nighttime sleep aid. Helps to reduce symptoms of menopause such as facial flushing, night sweats, sleep disturbances and nervousness. Clinically shown to help relieve symptoms of menopause such as facial flushing, night sweats, sleep disturbances and nervousness. Helps promote/maintain/support sexual health in menopausal women. Clinically shown to help promote/maintain/support sexual health in menopausal women. Helps support healthy mood balance during menopause. Helps support emotional aspects of sexual health in women. Helps to reduce cortisol levels, a biomarker of physical stress. Helps to reduce cortisol levels in the blood, a leading indicator of stress. Clinically shown to help reduce menopausal symptoms including hot flashes, night sweats, low energy, difficulty sleeping, difficulty concentrating, irritability/nervousness, muscle and joints discomfort, headaches, paresthesia (tingling, burning sensation of the skin), vertigo and vaginal dryness. MS-10 helps to provide menopausal symptom relief.

Testo originale in inglese.

Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.

Avvertenze in Canada

Cautions and Warnings : Consult a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen. If you suffer from any psychological disorder and/or condition such as frequent anxiety or depression, consult a healthcare practitioner prior to use. Sleep aid: Consult a healthcare practitioner/healthcare provider/healthcare professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia). Consult a healthcare practitioner prior to use if you are taking antidepressants. Avoid taking with alcohol or products that cause drowsiness.

Testo originale in inglese.

Scheda del prodotto

Altri nomi
(Genestra Brands) Meno Daily, (Genestra Brands) MenoPlus, (Genestra Brands) MenoPro
Titolare
Nestle Canada Inc. dba (Atrium Innovations/Genestra Brands/Pure Encapsulations/Garden of Life Canada/Trophic Canada/SISU/Wobenzym/Bountiful Canada Vitamins/Nature's Bounty/Vital Proteins Canada)
NPN o DIN-HM
80129321
Stato
Licenza attiva
Data della licenza
1 febbraio 2024
Data di revisione
10 aprile 2026
Forma
Capsule
Via di somministrazione
Orale
Tipo di domanda
Générale (non traditionelle)

Fonte

Scheda ufficiale Health Canada, licenza 80129321

Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Testo originale in inglese.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Testo originale in francese.

La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

  • Passiflora incarnata
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    PASSIONFLOWER -PASSIFLORA INCARNATA

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).

    Fonti citate da Health Canada (2)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach, 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002

    Condizione di applicazione: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condizione di applicazione: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    Fonti citate da Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).

    Fonti citate da Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    Fonti citate da Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    Reazioni avverse note

    Stop use if hypersensitivity/allergy occurs (EMA 2014).

    Fonti citate da Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    Monografia di Health Canada del 29 novembre 2024

Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.

Elenco nella revisione ufficiale del (registro: Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze).

Il prodotto è cambiato? Fotografi la confezione.

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Invio per analizzare, Maiusc+Invio per una nuova riga